Trial reportMedicine2025
High-concentration contrast media combined with low tube current for radiation dose reduction in head and neck computed tomography angiography: A prospective study.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of a personalized total iodine dose (TID) combined with fixed injection duration (FID) protocol using high-concentration (400 mgI/mL) iodinated contrast medium in CT portal venography: a randomized trial.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-concentration contrast media (HCCM) is a promising strategy to reduce radiation dose during computed tomography scan. This prospective study aims to assess whether the combination of HCCM and reduced tube current (mAs) can decrease radiation dose without compromising image quality in head and neck computed tomography angiography (CTA). A total of 68 consecutive patients (41 males, 27 females) with a mean age of 60.9 ± 10.9 years, referred for head and neck CTA, were randomly assigned to Group A (iodixanol 320, automatic mAs) and Group B (iomeprol 400, effective mAs reduced by a factor 0.64). CTA were performed with a tube voltage of 100 kV. Radiation dose was assessed by the volume CT dose index (CTDIvol), dose length product, and effective dose. Objective image quality was evaluated based on attenuation, signal-to-noise ratio, and contrast-to-noise ratio. Subjective image quality was rated using a 5-point Likert scale. Group B had significantly lower CTDIvol (4.22 ± 0.54 vs 6.48 ± 0.79 mGy) and dose length product (167.9 ± 24.5 vs 249.1 ± 35.7 mGy*cm) compared to Group A (P <.001). The effective dose in Group B was reduced by 32.5%. CT attenuation values for the internal carotid artery, middle cerebral artery, and aortic arch in Group B were significantly higher than those in Group A (P <.05). No significant differences were found in signal-to-noise ratio or contrast-to-noise ratio. The subjective quality for overall image and main head and neck arteries was significantly higher in Group B compared to Group A. In conclusion, the combination of HCCM and reduced mAs effectively reduces radiation dose without compromising image quality in head and neck CTA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.